Ionis Pharmaceuticals Inc IONS:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:00 PM EDT
39.21UNCH (UNCH)
Volume
188,813
Close
39.21quote price arrow up+0.94 (+2.46%)
Volume
1,066,558
52 week range
34.99 - 54.44
Loading...
  • Open38.78
  • Day High39.78
  • Day Low38.60
  • Prev Close38.27
  • 52 Week High54.44
  • 52 Week High Date01/12/24
  • 52 Week Low34.99
  • 52 Week Low Date05/16/23

Key Stats

  • Market Cap5.719B
  • Shares Out145.85M
  • 10 Day Average Volume1.10M
  • Dividend-
  • Dividend Yield-
  • Beta0.36
  • YTD % Change-22.49

KEY STATS

  • Open38.78
  • Day High39.78
  • Day Low38.60
  • Prev Close38.27
  • 52 Week High54.44
  • 52 Week High Date01/12/24
  • 52 Week Low34.99
  • 52 Week Low Date05/16/23
  • Market Cap5.719B
  • Shares Out145.85M
  • 10 Day Average Volume1.10M
  • Dividend-
  • Dividend Yield-
  • Beta0.36
  • YTD % Change-22.49

RATIOS/PROFITABILITY

  • EPS (TTM)-2.67
  • P/E (TTM)-14.68
  • Fwd P/E (NTM)-9.98
  • EBITDA (TTM)-376.27M
  • ROE (TTM)-98.27%
  • Revenue (TTM)776.62M
  • Gross Margin (TTM)98.72%
  • Net Margin (TTM)-49.54%
  • Debt To Equity (MRQ)430.10%

EVENTS

  • Earnings Date08/07/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Ionis Pharmaceuticals Inc

Profile

MORE
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy...
Joseph Loscalzo M.D., Ph.D.
Independent Chairman of the Board
Brett Monia Ph.D.
Chief Executive Officer, Director
Elizabeth Hougen
Chief Financial Officer, Executive Vice President - Finance
Eric Swayze Ph.D.
Executive Vice President - Research
Eugene Schneider M.D.
Executive Vice President, Chief Clinical Development Officer
Patrick O'Neil Esq.
Chief Legal Officer, General Counsel and Corporate Secretary
Address
2855 Gazelle Court
Carlsbad, CA
92010
United States

Top Peers

SYMBOLLASTCHG%CHG
BPMC
Blueprint Medicines Corp
106.79+1.33+1.26%
PBH
Prestige Consumer Healthcare Inc
66.46-5.01-7.01%
CORT
Corcept Therapeutics Inc
27.83+0.17+0.61%
AMPH
Amphastar Pharmaceuticals Inc
42.44+1.14+2.76%
HRMY
Harmony Biosciences Holdings Inc
29.70-0.16-0.54%